Selected research
Industry Research
Recombinant Vaccines Industry Research Report 2026
Market perspective
The global Recombinant Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Recombinant Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Recombinant Vaccines market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Recombinant Vaccines market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Recombinant Vaccines include Johnson & Johnson, Novartis AG, Merck & Co., Inc, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AstraZeneca Plc., Serum Institute of India Pvt. Ltd and Sanofi S A., among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Recombinant Vaccines market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Recombinant Vaccines.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Vaccines Market by Company
Johnson & Johnson
Novartis AG
Merck & Co., Inc
Pfizer Inc.
GlaxoSmithKline Plc.
Bayer AG
AstraZeneca Plc.
Serum Institute of India Pvt. Ltd
Sanofi S A.
Protein Science Corporation
Novavax, Inc
Green Cross Corporation
Emergent BioSolutions Inc
Dynavax Technologies Corporation
Bharat Biotech
Recombinant Vaccines Segment by Type
Vector Recombinant Vaccines
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Recombinant Vaccines Segment by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines
Recombinant Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Recombinant Vaccines companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vector Recombinant Vaccines
- Subunit Recombinant Vaccines
- Attenuated Recombinant Vaccines
Applications
- Recombinant Human Vaccines
- Animal Recombinant Vaccines
Companies covered
- Johnson & Johnson
- Novartis AG
- Merck & Co., Inc
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Bayer AG
- AstraZeneca Plc.
- Serum Institute of India Pvt. Ltd
- Sanofi S A.
- Protein Science Corporation
- Novavax, Inc
- Green Cross Corporation
- Emergent BioSolutions Inc
- Dynavax Technologies Corporation
- Bharat Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Recombinant Vaccines by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Vector Recombinant Vaccines
- 2.2.3 Subunit Recombinant Vaccines
- 2.2.4 Attenuated Recombinant Vaccines
- 2.3 Recombinant Vaccines by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Recombinant Human Vaccines
- 2.3.3 Animal Recombinant Vaccines
- 2.4 Assumptions and Limitations
3 Recombinant Vaccines Breakdown Data by Type
- 3.1 Global Recombinant Vaccines Historic Market Size by Type (2021-2026)
- 3.2 Global Recombinant Vaccines Forecasted Market Size by Type (2027-2032)
4 Recombinant Vaccines Breakdown Data by Application
- 4.1 Global Recombinant Vaccines Historic Market Size by Application (2021-2026)
- 4.2 Global Recombinant Vaccines Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Recombinant Vaccines Market Perspective (2021-2032)
- 5.2 Global Recombinant Vaccines Growth Trends by Region
- 5.2.1 Global Recombinant Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Recombinant Vaccines Historic Market Size by Region (2021-2026)
- 5.2.3 Recombinant Vaccines Forecasted Market Size by Region (2027-2032)
- 5.3 Recombinant Vaccines Market Dynamics
- 5.3.1 Recombinant Vaccines Industry Trends
- 5.3.2 Recombinant Vaccines Market Drivers
- 5.3.3 Recombinant Vaccines Market Challenges
- 5.3.4 Recombinant Vaccines Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Recombinant Vaccines Players by Revenue
- 6.1.1 Global Top Recombinant Vaccines Players by Revenue (2021-2026)
- 6.1.2 Global Recombinant Vaccines Revenue Market Share by Players (2021-2026)
- 6.2 Global Recombinant Vaccines Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Recombinant Vaccines Head Office and Area Served
- 6.4 Global Recombinant Vaccines Players, Product Type & Application
- 6.5 Global Recombinant Vaccines Manufacturers Established Date
- 6.6 Global Recombinant Vaccines Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Recombinant Vaccines Market Size (2021-2032)
- 7.2 North America Recombinant Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Recombinant Vaccines Market Size by Country (2021-2026)
- 7.4 North America Recombinant Vaccines Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Recombinant Vaccines Market Size (2021-2032)
- 8.2 Europe Recombinant Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Recombinant Vaccines Market Size by Country (2021-2026)
- 8.4 Europe Recombinant Vaccines Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant Vaccines Market Size (2021-2032)
- 9.2 Asia-Pacific Recombinant Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Recombinant Vaccines Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Recombinant Vaccines Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Recombinant Vaccines Market Size (2021-2032)
- 10.2 South America Recombinant Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Recombinant Vaccines Market Size by Country (2021-2026)
- 10.4 South America Recombinant Vaccines Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant Vaccines Market Size (2021-2032)
- 11.2 Middle East & Africa Recombinant Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Recombinant Vaccines Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Recombinant Vaccines Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson
- 12.1.1 Johnson & Johnson Company Information
- 12.1.2 Johnson & Johnson Business Overview
- 12.1.3 Johnson & Johnson Revenue in Recombinant Vaccines Business (2021-2026)
- 12.1.4 Johnson & Johnson Recombinant Vaccines Product Portfolio
- 12.1.5 Johnson & Johnson Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Recombinant Vaccines Business (2021-2026)
- 12.2.4 Novartis AG Recombinant Vaccines Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Merck & Co., Inc
- 12.3.1 Merck & Co., Inc Company Information
- 12.3.2 Merck & Co., Inc Business Overview
- 12.3.3 Merck & Co., Inc Revenue in Recombinant Vaccines Business (2021-2026)
- 12.3.4 Merck & Co., Inc Recombinant Vaccines Product Portfolio
- 12.3.5 Merck & Co., Inc Recent Developments
- 12.4 Pfizer Inc.
- 12.4.1 Pfizer Inc. Company Information
- 12.4.2 Pfizer Inc. Business Overview
- 12.4.3 Pfizer Inc. Revenue in Recombinant Vaccines Business (2021-2026)
- 12.4.4 Pfizer Inc. Recombinant Vaccines Product Portfolio
- 12.4.5 Pfizer Inc. Recent Developments
- 12.5 GlaxoSmithKline Plc.
- 12.5.1 GlaxoSmithKline Plc. Company Information
- 12.5.2 GlaxoSmithKline Plc. Business Overview
- 12.5.3 GlaxoSmithKline Plc. Revenue in Recombinant Vaccines Business (2021-2026)
- 12.5.4 GlaxoSmithKline Plc. Recombinant Vaccines Product Portfolio
- 12.5.5 GlaxoSmithKline Plc. Recent Developments
- 12.6 Bayer AG
- 12.6.1 Bayer AG Company Information
- 12.6.2 Bayer AG Business Overview
- 12.6.3 Bayer AG Revenue in Recombinant Vaccines Business (2021-2026)
- 12.6.4 Bayer AG Recombinant Vaccines Product Portfolio
- 12.6.5 Bayer AG Recent Developments
- 12.7 AstraZeneca Plc.
- 12.7.1 AstraZeneca Plc. Company Information
- 12.7.2 AstraZeneca Plc. Business Overview
- 12.7.3 AstraZeneca Plc. Revenue in Recombinant Vaccines Business (2021-2026)
- 12.7.4 AstraZeneca Plc. Recombinant Vaccines Product Portfolio
- 12.7.5 AstraZeneca Plc. Recent Developments
- 12.8 Serum Institute of India Pvt. Ltd
- 12.8.1 Serum Institute of India Pvt. Ltd Company Information
- 12.8.2 Serum Institute of India Pvt. Ltd Business Overview
- 12.8.3 Serum Institute of India Pvt. Ltd Revenue in Recombinant Vaccines Business (2021-2026)
- 12.8.4 Serum Institute of India Pvt. Ltd Recombinant Vaccines Product Portfolio
- 12.8.5 Serum Institute of India Pvt. Ltd Recent Developments
- 12.9 Sanofi S A.
- 12.9.1 Sanofi S A. Company Information
- 12.9.2 Sanofi S A. Business Overview
- 12.9.3 Sanofi S A. Revenue in Recombinant Vaccines Business (2021-2026)
- 12.9.4 Sanofi S A. Recombinant Vaccines Product Portfolio
- 12.9.5 Sanofi S A. Recent Developments
- 12.10 Protein Science Corporation
- 12.10.1 Protein Science Corporation Company Information
- 12.10.2 Protein Science Corporation Business Overview
- 12.10.3 Protein Science Corporation Revenue in Recombinant Vaccines Business (2021-2026)
- 12.10.4 Protein Science Corporation Recombinant Vaccines Product Portfolio
- 12.10.5 Protein Science Corporation Recent Developments
- 12.11 Novavax, Inc
- 12.11.1 Novavax, Inc Company Information
- 12.11.2 Novavax, Inc Business Overview
- 12.11.3 Novavax, Inc Revenue in Recombinant Vaccines Business (2021-2026)
- 12.11.4 Novavax, Inc Recombinant Vaccines Product Portfolio
- 12.11.5 Novavax, Inc Recent Developments
- 12.12 Green Cross Corporation
- 12.12.1 Green Cross Corporation Company Information
- 12.12.2 Green Cross Corporation Business Overview
- 12.12.3 Green Cross Corporation Revenue in Recombinant Vaccines Business (2021-2026)
- 12.12.4 Green Cross Corporation Recombinant Vaccines Product Portfolio
- 12.12.5 Green Cross Corporation Recent Developments
- 12.13 Emergent BioSolutions Inc
- 12.13.1 Emergent BioSolutions Inc Company Information
- 12.13.2 Emergent BioSolutions Inc Business Overview
- 12.13.3 Emergent BioSolutions Inc Revenue in Recombinant Vaccines Business (2021-2026)
- 12.13.4 Emergent BioSolutions Inc Recombinant Vaccines Product Portfolio
- 12.13.5 Emergent BioSolutions Inc Recent Developments
- 12.14 Dynavax Technologies Corporation
- 12.14.1 Dynavax Technologies Corporation Company Information
- 12.14.2 Dynavax Technologies Corporation Business Overview
- 12.14.3 Dynavax Technologies Corporation Revenue in Recombinant Vaccines Business (2021-2026)
- 12.14.4 Dynavax Technologies Corporation Recombinant Vaccines Product Portfolio
- 12.14.5 Dynavax Technologies Corporation Recent Developments
- 12.15 Bharat Biotech
- 12.15.1 Bharat Biotech Company Information
- 12.15.2 Bharat Biotech Business Overview
- 12.15.3 Bharat Biotech Revenue in Recombinant Vaccines Business (2021-2026)
- 12.15.4 Bharat Biotech Recombinant Vaccines Product Portfolio
- 12.15.5 Bharat Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst